Published 6 days ago • loading... • Updated 5 days ago
VolitionRx Limited Announces Third Quarter 2026 Financial Results and Business Update
Revenue rose 157% as VolitionRx cut expenses 14% and advanced licensing talks for its Capture-Seq technology with major diagnostics companies.
Summary by Antelope Valley Press
10 Articles
10 Articles
VolitionRX (NYSEAMERICAN:VNRX) Issues Quarterly Earnings Results
VolitionRX (NYSEAMERICAN:VNRX – Get Free Report) announced its quarterly earnings results on Thursday. The medical research company reported ($0.21) earnings per share for the quarter, topping the consensus estimate of ($0.38) by $0.17, FiscalAI reports. The company had revenue of $1.61 million for the quarter, compared to analyst estimates of $0.71 million. VolitionRX Trading Down […]
Coverage Details
Total News Sources10
Leaning Left1Leaning Right2Center6Last Updated67% Center
Bias Distribution
- 67% of the sources are Center
67% Center
11%
C 67%
R 22%
Factuality
To view factuality data please Upgrade to Premium











